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Objectives: Safflower yellow (SY) is the main effective ingredient of Carthamus tinctorius
L. It has been reported that SY plays an important role in anti-inflammation, anti-platelet
aggregation, and inhibiting thrombus formation. In present study, we try to investigate
the effects of SY on body weight, body fat mass, insulin sensitivity in high fat diet
(HFD)-induced obese mice.
Methods: HFD-induced obese male ICR mice were intraperitoneally injected with SY
(120mg kg−1) daily. Eight weeks later, intraperitoneal insulin tolerance test (IPITT), and
intraperitoneal glucose tolerance test (IPGTT) were performed, and body weight, body fat
mass, serum insulin levels were measured. The expression of glucose and lipid metabolic
related genes in white adipose tissue (WAT) were determined by RT-qPCR and western
blot technologies.
Results: The administration obese mice with SY significantly reduced the body fat mass
of HFD-induced obese mice (P < 0.05). IPITT test showed that the insulin sensitivity of
SY treated obese mice were evidently improved. The mRNA levels of insulin signaling
pathway related genes including insulin receptor substrate 1(IRS1), PKB protein kinase
(AKT), glycogen synthase kinase 3β (GSK3β) and forkhead box protein O1(FOXO1) in
mesenteric WAT of SY treated mice were significantly increased to 1.9- , 2.8- , 3.3- , and
5.9-folds of that in HFD-induced control obese mice, respectively (P < 0.05). The protein
levels of AKT and GSK3β were also significantly increased to 3.0 and 5.2-folds of that in
HFD-induced control obese mice, respectively (P < 0.05). Meanwhile, both the mRNA
and protein levels of peroxisome proliferator-activated receptorgamma coactivator 1α
(PGC1α) in inguinal subcutaneous WAT of SY group were notably increased to 2.5 and
3.0-folds of that in HFD-induced control obese mice (P < 0.05).
Conclusions: SY significantly reduce the body fat mass, fasting blood glucose and
increase insulin sensitivity of HFD-induced obese mice. The possible mechanism is to
promote the browning of subcutaneousWAT and activate the IRS1/AKT/GSK3β pathway
in visceral WAT. Our study provides an important experimental evidence for developing
SY as a potential anti-obesity and anti-diabetic drug.
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INTRODUCTION
Obesity is presented as the energy metabolism imbalance with
low energy expenditure and high energy uptake, which leads to
excessive and abnormal accumulation of fat in our body. It has
become a worldwide public health problem due to its strong
relationship with diabetes, dyslipidemia, hypertension, coronary
heart disease, stroke, sleep apnea, and several kinds of tumors.
The costs of treatments for obesity and its related implications
have become serious economic burden for health improvement
all over the world.
Therefore, weight loss drug development has attracted the
attention of researchers around the world. There are two kinds
of anti-obesity medications in current or recent medical market.
One is the inhibitors of fat absorption, such as orlistat. Another
is the modifiers of central nervous system neurotransmission
of norepinephrine, dopamine and serotonin, such as sibutrimin
(Padwal et al., 2003). The function of these drugs improving
insulin resistance is often dependent on the weight loss, rather
than on the direct effect to the target genes. And these anti-
obesity drugs havemany adverse events that outweigh themodest
benefits of treatment (Ioannides-Demos et al., 2011). Orlistat
can lead to obligate increases in undigested stool triglycerides
which may cause oily spotting, flatus with discharge, fecal
urgency, fatty oily stool, increased defecation, fecal incontinence,
and other considerable gastrointestinal adverse effects (Yanovski
and Yanovski, 2014). The central acting drugs sibutrimin and
phentermine can cause elevation in heart rate and blood pressure,
insomnia, dry mouth, dizziness, tremors, headache, vomiting,
and anxiety (Yanovski and Yanovski, 2014). These adverse effects
lead to a decline in the life quality of patients and are one reason
of their therapy interruption. Traditional Chinese medicine is
gradually being paid close attention because of its beneficial
features including multi-target effects, rich resources, less side
effects and safety. So it is necessary to explore the weight loss
drugs or ingredients from traditional Chinese medicine by using
modern molecular biological technology.
Saﬄower yellow (SY), the main effective ingredient of
Carthamus tinctorius L, has many different functions, including
anti-inflammation, anti-platelet aggregation, inhibiting
thrombus formation, anti-oxidation and inhibiting tumor
angiogenesis (Liu L. et al., 2012; Liu S. X. et al., 2012; Li et al.,
2013; Wang et al., 2014). The parenteral solution, tablets
or other dosage forms of Carthamus tinctorius L have been
approved by China Food and Drug Administration (CFDA) as
an adjunctive therapy for cardiovascular and cerebrovascular
diseases. Our previous studies showed that hydroxysaﬄor yellow
Abbreviations: SY, saﬄower yellow; CFDA, China Food andDrug Administration;
HSYA, hydroxysaﬄor yellow A; HSL, hormone sensitive lipase; HFD, high fat diet;
WAT, white adipose tissue; IPITT, intraperitoneal insulin tolerance test; IPGTT,
intraperitoneal glucose tolerance test; PPIA, Cyclophilin A; HRP, horseradish
peroxidase; ECL, enhanced chemiluminescence; SF, standard food; IRS1, insulin
receptor substrate 1; GSK3β, glycogen synthase kinase 3β; FOXO1, forkhead box
protein O1; PGC1α, peroxisome proliferator-activated receptorgamma coactivator
1α; UCP1, uncoupling protein 1; FNDC5, fibronectin type III domain containing
5; PRDM16, PR domain containing 16; CIDEA, cell death-inducing DNA
fragmentation factor, alpha subunit-like effector A; PI3K, phosphatidylinositol 3
kinase.
A (HSYA), the main active ingredient in SY, could inhibit the
proliferation and adipogenesis of murine 3T3-L1 preadipocytes
by promoting lipolytic-specific enzyme hormone sensitive lipase
(HSL) expression (Zhu et al., 2014). However, it is still unknown
whether SY has effects on the body weight and insulin sensitivity
in vivo. In this study, we try to explore the effects of SY on body
weight, body fat mass, insulin sensitivity and its possible tissue
targets in high fat diet (HFD)-induced obese mice. Our results
showed that SY could reduce body fat mass of HFD-induced
obese mice by promoting the browning of subcutaneous white
adipose tissue (WAT), and decrease blood glucose levels and
increase insulin sensitivity through activating IRS1/AKT/GSK3β




Eight-week-old male ICR mice (25∼27 g) were obtained from
Beijing HFK Bioscience Co., LTD. SY was obtained from
Prof. Ming Jin (Department of Pharmacology, Beijing Anzhen
Hospital, Capital Medical University) who isolated and purified
SY from the aqueous extracts of C. tinctorius L. by macroporous
resin-gel column chromatography and determined a purity of
95.4% by HPLC as they described previously (Zang et al., 2008;
Song et al., 2013). All mice were randomly divided into standard
food (SF) group (n = 10) and HFD group (n = 25). Eight
weeks later, mice fed with HFD were weighed and divided into
HFD group (n = 13) and SY intervention group (SY group,
n = 12). All mice were housed in standard cages with access
to food and water ad libitum in a temperature-controlled room
(21–23◦C) and under a 12 h dark/light cycle. Mice in SY group
were intraperitoneally injected with SY at a concentration of
120mg kg−1 daily, and mice in SF and HFD groups were
intraperitoneally injected with saline in equal volume daily.
The body weight of mice was measured once a week. After
8 weeks intervention, the intraperitoneal insulin tolerance test
(IPITT) and intraperitoneal glucose tolerance test (IPGTT) were
performed and mice were killed by cervical vertebra dislocation.
Inguinal subcutaneous and visceral WAT including mesenteric,
epididymal, and perirenal WAT was dissected, weighted and
then frozen immediately in liquid nitrogen for the further
analysis. Serum insulin, fasting blood glucose (FBG), uric
acid (UA), Lipoprotein (a) [Lp (a)], high-sensitivity C-reactive
protein (hsCRP), triglycerides (TG), total cholesterol (TC), free
fatty acids (FFA), low density lipoprotein-cholesterol (LDL-
c), and high density lipoprotein-cholesterol (HDL-c) of mice
were measured by routine automated laboratory methods. All
animal experimental protocols were carried out according to
the standards of the Guide for the Care and Use of Laboratory




RT-qPCR was performed with SYBR green fluorescent dye using
an ABI7500 PCR system as previously described (Livak and
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Schmittgen, 2001; Gong et al., 2009). In brief, adipose tissue total
RNA was isolated by using E.Z.N.A Total RNA Kit I (Omega
Biotek, USA, Lot R6834-01). 0.5 µg of total RNA was used to
produce cDNA using an RT-qPCR system including Omniscript
RT kit (Qiagen, USA, Lot 205111), Oligo (dT) primer (Promega,
capsule, Lot C110A), and RNA enzyme inhibitor (Promega,
capsule, Lot N251A). Housekeeping gene Cyclophilin A (PPIA)
was used as internal control to normalize the expression of target
genes. The primer sequences of target genes and internal control
gene were listed in Table S1. RT-qPCR was duplicated for 2 wells
in a final volume of 20 µL. The mRNA expression levels of
target genes in arbitrary unit were acquired from the value of the
threshold cycle (Ct) of the RT-qPCR as related to that of PPIA
using the comparative Ct method through the formula 2−11CT.
All samples were normalized to the PPIA values and the results
expressed as fold changes of Ct value relative to control by using
the formula 2−11Ct (Gong et al., 2009, 2010).
Western Blot Analysis
Total proteins were extracted from adipose tissue samples
using a Total Protein Extraction kit (Applygen, Beijing, China)
according to the manufacturer’s instructions. The protein
contents were determined using the Coomassie Protein Kit
(Applygen, Beijing, China). Total protein concentration was
about 2 µg ul−1. The proteins were separated by SDS-PAGE
and transferred onto nitrocellulose membranes (Millipore, USA)
by using a wet transfer (BIO-RAD, California, USA). The
membranes were blocked with 5% non-fat milk diluted using
TBST (Jiangchenyuanyuan Biotechnology, Beijing, China) and
then incubated with primary antibodies at 4◦C overnight.
Mouse immunoglobulin G (IgG) anti-β-actin (Sigma, USA),
anti-PGC1α (Millipore, USA), and Rabbit IgG anti-AKT
(Cell Signaling Technology, USA), anti-GSK3β (Cell Signaling
Technology, USA) were used as the primary antibodies (1:1000
to 1:4000 diluted in 5% non-fat milk). The membranes were
washed with TBST and then incubated with horseradish
peroxidase (HRP)-conjugated goat antibodies (Applygen, China)
(1:1000 diluted 5% non-fat milk) at room temperature for 1.5
h. The specific protein bands were visualized by enhanced
chemiluminescence (ECL) according to the manufacturer’s
instructions (Applygen, Beijing, China). The bands were then
quantified by Quantity One software (Version 4.6.9, BIO-RAD,
California, USA). β-actin was used as an internal control for
target proteins analysis.
Statistical Analysis
Results were expressed as mean ± standard error (SE). The Ct
values obtained in RT-qPCR analysis were transformed through
the formula 2−11CT to linear relationship. The density ratio of
target protein to reference protein was calculated to evaluate the
protein expression differences. Univariate analysis of variance
(ANOVA) method was used for data analysis. Dunnett’s T3
method was used for two group comparisons depending on the
homogeneity of variance. Skewed data were ln-transformed and
Mann-Whitney U test was used if data were still not normally
distributed. All statistical computations were run on SPSS 13.0
for Windows (SPSS Inc, Chicago, IL, USA), p < 0.05 was
considered as statistically significant.
RESULTS
Effects of SY on Body Fat Mass,
Biochemical Parameters, and Insulin
Sensitivity in HFD Induced Obese Mice
Body weight of mice fed with HFD for 8 weeks were significantly
increased and reached to 1.22-folds of mice fed with standard
food (SF) (53.8 ± 1.6 g vs. 44.0 ± 1.1 g, P < 0.05), implying
obese mice model was established successfully (Figure S1). The
body weight of obese mice in HFD group was always significantly
higher than those in SF group during the period of 8-week SY
administration (Figure S2, P < 0.05), and it was 126% of that in
SF group (Table 1) at the end of administration. However, there
was no significant body weight reduction was observed in SY
group mice when compared with that in HFD group (Table 1).
Meanwhile, the mass of subcutaneous, mesenteric, perirenal, and
epididymal fat tissue of obese mice were significantly increased
to 5.12, 1.87, 4.48, and 3.47-folds of that in SF group mice (all
P < 0.05). Interestingly, the fat mass of these locations in SY
administration mice was significantly decreased by 42.6, 30.0,
TABLE 1 | Effects of SY on body weight, body fat contents and
biochemical parameters in HFD-induced obese mice.
SF (n = 10) HFD (n = 13) SY (n = 12)
Body weight (g)
before administration
44.00± 1.06 54.83±2.26a 53.00± 2.03
Body weight (g)
after administration#
44.97± 0.90 56.72±2.19a 54.36± 3.16
Subcutaneous fat mass
(g)
0.33± 0.11 1.69±0.84a 0.97± 0.65b
Mesenteric fat mass (g) 0.63± 0.22 1.18±0.57a 0.85± 0.40
Perirenal fat mass (g) 0.25± 0.07 1.12±0.59a 0.67± 0.36b
Epididymal fat mass (g) 0.64± 0.14 2.22±0.85a 1.67± 0.80
Total fat mass (g) 1.85± 0.14 6.21±0.71a 4.16± 0.58b
Percentage of fat
mass* (%)
4.70± 0.31 11.91±1.01a 8.41± 0.96b
FBG (mmol/L) 5.22± 0.75 8.00±0.78a 5.83± 0.68b
UA (µmol/L) 191.90± 7.25 195.08±12.85 264.83± 24.10b
TC (mmol/L) 4.25± 0.32 4.90±0.27 4.76± 0.30
TG (mmol/L) 0.43± 0.05 0.40±0.07 0.50± 0.05
HDL-c (mmol/L) 2.23± 0.13 2.33±0.12 2.22± 0.10
LDL-c (mmol/L) 0.47± 0.08 0.54±0.05 0.60± 0.05
Lp(a) (mg/L) 4.10± 0.53 4.77±0.47 5.67± 0.38
hsCRP (mg/L) 0.08± 0.01 0.08±0.01 0.09± 0.01
FFA (µmol/L) 1287.50± 109.83 1129.85±82.66 1201.67± 66.08
Insulin (ng/ml) 0.47± 0.05 0.52±0.06 0.73± 0.11
Values are means ± SE; SF, standard food; HFD, high fat diet; SY, safflower yellow;
FBG, fasting blood glucose; UA, uric acid; TC, total cholesterol; TG, triglycerides; HDL-
c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; Lp(a),
lipoprotein (a); hsCRP, high-sensitivity C-reactive protein; FFA, free fatty acids; #,body
weight after administration for 8 weeks; *, Total fat mass/Body weight; a,compared with
SF group, P < 0.05; b,compared with HFD group, P < 0.05.
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40.2, and 24.8% of that in HFD group mice, respectively, as
presented in Table 1, and significant differences were observed
in subcutaneous and perirenal adipose tissue (all P < 0.05).
As shown in Table 1, the total fat mass and the percentage of
body weight occupied by the total fat mass of HFD-induced
obese mice were significantly increased to 3.36 and 2.53-folds in
comparison with that in SF group (all P < 0.05). After 8 weeks,
the total fat mass and the percentage in SY administration mice
was significantly decreased by 33.0 and 29.4% of that in HFD
group mice, respectively (P < 0.05).
The changes of biochemical parameters in obese mice treated
with SY for 8 weeks were displayed in Table 1. The obese mice
in HFD group had higher FBG levels as compared with that in
SF group (8.00 ± 0.78 mmol L−1 vs. 5.22±0.75 mmol L−1, P <
0.05). After administration the mice with SY for 8 weeks, the FBG
levels were significantly reduced by 27.1% as compared with that
in HFD group (5.83± 0.68 mmol L−1 vs. 8.00± 0.78 mmol L−1,
P < 0.05). Meanwhile, the UA levels of mice in SY group were
significantly increased by 35% in comparison with that in HFD
group (264.83± 24.10 µmol L−1 vs. 195.08± 12.85 µmol L−1, P
< 0.05). However, there was no significant difference with regard
to TC, TG, HDL-c, LDL-c, Lp (a), hsCRP, FFA, and insulin levels
in these three groups.
Next, the 2-h IPITT and IPGTT tests were done to explore the
effect of SY on glucose metabolism. As presented in Figure 1A,
the glucose curve in IPITT tests showed that glucose at every time
point in HFD group was increased when compared with those
FIGURE 1 | IPITT and IPGTT in the three groups. After 8 weeks
intervention, the intraperitoneal insulin tolerance test (IPITT) (A) and
intraperitoneal glucose tolerance test (IPGTT) (B) in mice were performed.
Glucose levels at 0 (before injection), 30, 60, 90, 120 min were measured.*P <
0.05 vs. SF group; #P < 0.05 vs. HFD group.
in SF group, and significantly increased by 33.8 and 67.9% at 0,
30min (P < 0.05). After administration obese mice with SY for
8 weeks, the glucose levels at every time point was significantly
reduced by 22.2, 40.4, and 41.9% at 0, 30, 60min in IPITT tests
when compared with those in HFD group (P < 0.05). However,
there was no significant difference of glucose level at every point
in IPGTT among the three groups as shown in Figure 1B (P >
0.05).
Effects of SY on the Expression of Genes
Involved in Insulin Signaling Pathways in
WAT of Obese Mice
In order to explore the tissue targets of SY decreasing fasting
blood glucose and increasing insulin sensitivity, the expression
of genes involved in insulin signaling pathway including IRS1,
AKT, GSK3β, and FOXO1 were investigated. As presented in
Figure 2A, themRNA levels of IRS1, AKT, GSK3β, and FOXO1 in
mesenteric WAT of HFD-induced obese mice were significantly
decreased by 62.9, 73.8, 83.7, and 88.7% of that in SF mice (P <
FIGURE 2 | Effects of SY on the mRNA and protein levels of genes
involved in insulin signaling pathways in mesenteric white adipose
tissue of obese mice. (A) The mRNA levels of IRS1, AKT, GSK3β, and
FOXO1 in mesenteric white adipose tissue of mice in SF, HFD and SY group
were determined by RT-qPCR analysis. The RT-qPCR was repeated for two
times with n = 8 for each group. (B) The protein levels of AKT and GSK3β in
mesenteric white adipose tissue of mice in SF, HFD, and SY group were
determined by western blot analysis. The blots were repeated for three times
with n = 8 for each group. *P < 0.05 vs. SF group; #P < 0.05 vs. HFD group.
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0.05). After administration obese mice with SY for 8 weeks, the
mRNA levels of these genes were notably increased to 1.9-, 2.8-,
3.3-, and 5.9-fold of that in HFD-induced obese mice (P < 0.05).
In consistent with the changes in transcription levels, the protein
levels of AKT and GSK3β in mesenteric WAT of obese mice
were also significantly decreased by 75.0 and 74.2%, respectively,
in comparison with SF mice (Figure 2B, P < 0.05) and notably
increased to 3.0- and 5.2-fold of that in HFD-induced obese mice,
respectively, after administration these mice with SY for 8 weeks
(Figure 2B, P < 0.05).
As what we did in the above mesenteric WAT, inguinal
subcutaneous WAT was also used to investigate the changes
of the insulin signaling pathway related genes after SY
administration. As shown in Figure 3A, the mRNA levels of AKT
and FOXO1 in inguinal subcutaneous WAT of HFD-induced
obese mice were significantly decreased by 45.3 and 65.9% of that
in SF mice (P < 0.05), but the mRNA levels of IRS1 and GSK3β
were not significantly changed (P > 0.05). After administration
obese mice with SY for 8 weeks, the mRNA levels ofAKT, GSK3β,
FIGURE 3 | Effects of SY on the mRNA and protein levels of genes
involved in insulin signaling pathways in subcutaneous white adipose
tissue of obese mice. (A) The mRNA levels of IRS1, AKT, GSK3β, and
FOXO1 in subcutaneous white adipose tissue of mice in SF, HFD, and SY
group were determined by RT-qPCR analysis. The RT-qPCR was repeated for
two times with n = 8 for each group. (B) The protein levels of AKT and GSK3β
in subcutaneous white adipose tissue of mice in SF, HFD, and SY group were
determined by western blot analysis. The blots were repeated for three times
with n = 8 for each group. *P < 0.05 vs. SF group; #P < 0.05 vs. HFD group.
and IRS1 were significantly increased to 1.6-, 1.5-, and 3.3-fold
of that in HFD-induced obese mice (P < 0.05), but the mRNA
levels of FOXO1 were not significantly changed (P > 0.05).
However, inconsistent with the changes in transcription level, the
protein levels of AKT and GSK3β in subcutaneous WAT had
no significant changes among the three groups as presented in
Figure 3B (P > 0.05).
Effects of SY on the Expression of Genes
Involved in the Browning of WAT in
Adipose Tissue
In order to explore the tissue targets of SY decreasing fat content,
the expression of genes involved in the browning of WAT
including PGC1α, UCP1, FNDC5, PRDM16, and CIDEA were
investigated. As presented in Figure 4A, the mRNA levels of
PGC1α and UCP1 in mesenteric WAT of HFD-induced obese
mice were significantly decreased by 87.9 and 94.5% of that in
SF mice (P < 0.05). After administration obese mice with SY
for 8 weeks, the mRNA levels of these genes were significantly
increased to 6.2- and 8.6-fold of that in HFD-induced obese
mice (P < 0.05). However, inconsistent with the changes in
transcription levels, the protein levels of PGC1α and UCP1 in
mesentericWAT had no significantly differences among the three
groups as presented in Figure 4B (P > 0.05).
As what we did in the above mesenteric WAT, inguinal
subcutaneous WAT was also used to investigate the changes
of the above five genes after SY administration. As shown in
Figure 5A, the mRNA levels of PGC1α, FNDC5, and PRDM16 in
inguinal subcutaneous WAT of HFD-induced obese mice were
not significantly changed as compared with SF mice (P > 0.05).
After administration obese mice with SY for 8 weeks, the mRNA
levels of these genes were significantly increased to 2.5- , 6.4- ,
and 2.1-folds of that in HFD-induced obese mice (P < 0.05). In
agreement with the changes in transcription levels, the protein
levels of PGC1α in subcutaneous WAT of obese mice were
significantly decreased by 87.0% in comparison with SF mice (P
< 0.05), while increased to 3.0-fold of that in HFD-induced obese
mice after SY administration as shown in Figure 5B (P < 0.05).
However, the mRNA levels of UCP1 in inguinal subcutaneous
WAT had no significant difference among the three groups.
Additionally, the mRNA levels of CIDEA, a characteristic gene of
classical brown adipose tissue, in inguinal subcutaneous WAT of
HFD-induced obese mice were significantly decreased by 68.2%
of that in SF mice (P < 0.05). However, the mRNA levels of this
gene were not significantly changed after administration these
mice with SY for 8 weeks as shown in Figure 5A (P > 0.05).
DISCUSSION
SY is the main ingredient of Carthamus tinctorius L which is
one kind of the saﬄower plant. It contains flavonols, chalcones,
alkaloids and other chemical compositions. SY has a structure
of chalcone and is a kind of water-soluble composition. SY
has been widely used in the treatment of cardiovascular and
cerebrovascular ischemic disease in clinical practice.
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FIGURE 4 | Effects of SY on the mRNA and protein levels of genes
involved in the browning of white adipose tissue in mesenteric white
adipose tissue of obese mice. (A) The mRNA levels of PGC1α and UCP1 in
mesenteric white adipose tissue of mice in SF, HFD, and SY group were
determined by RT-qPCR analysis. The RT-qPCR was repeated for two times
with n = 8 for each group. (B) The protein levels of PGC1α in mesenteric white
adipose tissue of mice in SF, HFD, and SY group were determined by western
blot analysis. The blots were repeated for three times with n = 8 for each
group. *P < 0.05 vs. SF group; #P < 0.05 vs. HFD group.
At present, many pharmacological effects of SY have
already been proved, including anti-platelet aggregation, anti-
inflammation, anti-oxidative stress, anti-fibrosis and so on. Our
study for the first time demonstrated that SY could reduce
the body fat mass, fasting blood glucose and increase insulin
sensitivity of HFD-induced obese mice.
Insulin signaling pathway is a key element for insulin
sensitivity. Insulin binds to the insulin receptor to cause
a series of protein phosphorylation cascade through
IRS/phosphatidylinositol 3 kinase (PI3K)/AKT pathway,
FIGURE 5 | Effects of SY on the mRNA and protein levels of genes
involved in the browning of white adipose tissue in subcutaneous
white adipose tissue of obese mice. (A) The mRNA levels of PGC1α,
UCP1, FNDC5, PRDM16, and CIDEA in subcutaneous white adipose tissue of
mice in SF, HFD, and SY group were determined by RT-qPCR analysis. The
RT-qPCR was repeated for two times with n = 8 for each group. (B) The
protein levels of PGC1α in subcutaneous white adipose tissue of mice in SF,
HFD, and SY group were determined by western blot analysis. The blots were
repeated for three times with n = 8 for each group. *P < 0.05 vs. SF group;
#P < 0.05 vs. HFD group.
and eventually lead to glucose uptake and gene expression
related with glucose metabolism. On the condition of obesity
and its related metabolic abnormalities, the impaired insulin
signaling pathway usually leads to insulin resistance.
AKT (also known as PKB), which is a serine / threonine
specific protein kinase (Gonzalez and Mcgraw, 2009) plays
a crucial role in the insulin signaling pathway (Mora et al.,
2004). The main function of AKT pathway is promoting glucose
uptake by muscle and adipose tissue and increasing hepatic
glycogen synthesis. Meanwhile, it also inhibited glucose release
from hepatocytes and gluconeogenesis (Steinberg and Kemp,
2009). The enhancement of AKT pathway can improve insulin
sensitivity through affecting GSK3β and other downstream
factors. In the present study, the mRNA and protein expression
levels of genes involved in AKT pathway in visceralWAT of obese
mice were significantly decreased. This phenomenon represented
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the impairment of insulin signaling pathway in visceral WAT.
After SY intervention for 8 weeks, the mRNA and protein
expression levels of AKT and GSK3βwere significantly increased.
However, the similar phenomenon was not observed in the
subcutaneous WAT. These results suggested that SY may play
a different role in adipose tissue from different locations. SY
decreased FBG and improved insulin sensitivity mainly through
the recovery of the function of insulin signaling pathway in
visceral WAT, rather than in subcutaneous WAT. In agreement
with our results, Li et al. (2014) found that insulin resistance
induced by liquid fructose in adipose tissue of rat could be
reduced through increasing the protein expression levels of AKT
and activating its signaling pathway. Liu and Wang et al also
found that SY could increase the protein expression levels of AKT
in myocardial cells (Liu S. X. et al., 2012) and cardiac muscle
tissue (Wang, 2008). All these findings, together with our results,
suggested that SY improved insulin sensitivity and decreased
blood glucose level through its effects on the IRS1/AKT/GSK3β
pathway in visceral WAT.
Obesity usually represents as weight gain, but its most
important characteristic is the abnormal increase of body fat
contents. Reducing body fat content could effectively improve
insulin sensitivity and decrease blood glucose. In the present
study, we observed the decrease of fat content and percentage
in SY-treated obese mice. So the effects of SY on the reduction
of FBG and the improvement of insulin sensitivity may also be
the subsequent effects of the decrease of body fat contents. It
was found that the glucose uptake rate by insulin stimulating
was negatively correlated with abdominal fat content in adipose
tissue of patients with abdominal obesity (Virtanen et al., 2005).
Galgani et al. (2013) also found high expression of adipose
gene (adp/WDTC1) was associated with adipose tissue reduction
and glucose utilization increase in human adipose tissue, while
inhibition of lipid formation was found to be related with adp
over expression in mice. Consistently, studies performed by
Lucas et al. (2012) and Choi et al. (2007) also showed that insulin
sensitivity improved while fat content decreased in obese mice.
Therefore, apart from the stimulatory role of SY on the insulin
signaling pathway, the effects of SY improving insulin sensitivity
and reducing blood glucose were supposed to be partly associated
with the reduction of body fat contents in HFD-induced obese
mice.
There are two traditional types of adipose tissue with different
functions, white and brown adipose tissue. In recent years, they
were considered to exist together and could be transformed into
each other under certain conditions including cold stimulation
and β3 adrenergic receptor agonist treatment (Collins et al.,
1997; Ghorbani and Himms-Hagen, 1997; Ghorbani et al., 1997;
Giordano et al., 1998; Granneman et al., 2005; Vitali et al.,
2012). The transformation from WAT to brown adipose tissue
was called the browning of WAT (Barbatelli et al., 2010; Vitali
et al., 2012). PGC1α, a transcriptional coactivator, is involved
in this process. It was considered as a key regulator and could
up-regulate the expression of FNDC5 to promote the browning
of WAT (Bostrom et al., 2012). PRDM16 (Seale et al., 2011)
was also considered to be another important regulator involved
in this process. In the present study, we for the first time
found that SY could reduce the fat mass of obese mice. Further
research demonstrated that the mRNA expression levels of
PGC1α, FNDC5, PRDM16, and the protein expression level of
PGC1α in the subcutaneous WAT were significantly increased.
All these results implied that SY may reduce the fat mass of
obese mice by promoting the browning of the subcutaneous
WAT. However, the protein expression level of PGC1α had no
significant difference inmesentericWAT after SY administration.
It was suggested that the mechanism of SY promoting the
browning of WAT may be different in the adipose tissue from
different locations. Similar to our results, Haruya (Ohno et al.,
2012) et al found that only subcutaneous WAT could be induced
to browning by PPARγ agonists through the activation of the
PRDM16 pathway. Seale et al. (2011) and many other studies
(Wu et al., 2012) also found that the browning phenomenon
was more common in the subcutaneous adipose tissue in
comparison with visceral adipose tissue in mice. That may be
due to the different effects on the regulation of metabolism
between subcutaneous and visceral WAT. Visceral WAT was
significantly associated with insulin resistance and development
of diabetes and metabolic syndrome (Neeland et al., 2013).
Conversely, subcutaneous WAT was considered to be beneficial
for metabolism (Foster et al., 2013). Overall, SY could reduce
the fat mass of HFD-induced obese mice and the mechanism
may be involved in promotion of the browning of subcutaneous
WAT rather than visceral WAT. Another explanation for the
mechanism by which SY reduced the fat mass of HFD-induced
obese mice was from our previous study which demonstrated
that HSYA, the main effective ingredient of SY, could decrease
the lipid accumulation in 3T3-L1adipocytes by promoting the
lipolytic-specific enzyme HSL expression. The similar results
were obtained both in vivo and vitro studies which also found
that the different concentration of SY (20, 40, and 80mg kg−1)
(Zhang et al., 2010) and HSYA (Yu et al., 2011) could decrease
the triglyceride contents in HFD-induced hyperlipidemia Wistar
rats (Zhang et al., 2010) and steroid-induced (Yu et al., 2011)
bone marrow mesenchymal stem cells from Sprague Dawley
rats. Therefore, the fat mass reduction in SY treated mice
observed in our present study may also be the result of the
enhanced lipolysis by promoting the expression of HSL, the
key enzyme in the fat metabolism regulation in adipose tissue
(Lampidonis et al., 2011).
An animal experiment performed by Zhang et al. (2010)
found that SY could reduce the serum TG, TC, LDL-c levels
and increase HDL-c level in HFD-induced obese mice. The same
phenomenon was also observed in our present study. That may
be due to the dependency of long-term intervention which was
a characteristic of traditional Chinese medicine. Besides, the
difference of drug delivery methods and the sex of mice may be
reasons. Zhang et al. (2010) treated the mice with intravenous
injection, and half female mice were chosen in their study.
Estrogen could improve glucose tolerance, insulin sensitivity
(Riant et al., 2009) and reduce TG, TC, LDL-c levels (Homma
et al., 2000; Amengual-Cladera et al., 2012) by promoting the
activity and expression of lipoprotein lipase with appropriate
dose (Pickar et al., 1998). Finally, the increase of UA level was
also observed in the SY treated obese mice, but the mechanism is
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still unclear. Further studies were needed to be done to clarify the
possible mechanism in the future.
In summary, SY could significantly reduce the body fat mass
and FBG, increase insulin sensitivity of HFD-induced obese
mice. The possible mechanism is to promote the browning of
subcutaneous WAT and activate the IRS1/AKT/GSK3β insulin
signaling pathway in visceral WAT. Our study provides an
important experimental evidence for developing SY as a potential
anti-obesity and anti-diabetic drug.
AUTHOR CONTRIBUTIONS
HZ designed the experiments, analyzed data and revised
the primary manuscript. XW did the molecular biological
experiments, analyzed data and wrote the primary manuscript.
HP supervised the experiments. YD did the animal experiments.
NL, LW, and HY supervised the experiments, especially
the biochemical parameters measurements. FG designed the
experiment, supervised the whole experiments and revised the
primary manuscript.
FUNDING
The study was supported by grants from the National
Natural Science Foundation of China (Nos.30600836,81471024
for HZ, Nos.30540036, 30771026, 81370898 for FG), the
Natural Science Foundation of BeijingMunicipality (No.7082079
for FG), the National Key Program of Clinical Science
(WBYZ2011-873 for FG and HZ) and PUMCH Foundation
(2013-020 for FG).
SUPPLEMENTARY MATERIAL




Amengual-Cladera, E., Llado, I., Gianotti, M., and Proenza, A. M. (2012).
Retroperitoneal white adipose tissue mitochondrial function and adiponectin
expression in response to ovariectomy and 17beta-estradiol replacement.
Steroids 77, 659–665. doi: 10.1016/j.steroids.2012.02.012
Barbatelli, G., Murano, I., Madsen, L., Hao, Q., Jimenez, M., Kristiansen, K.,
et al. (2010). The emergence of cold-induced brown adipocytes in mouse
white fat depots is determined predominantly by white to brown adipocyte
transdifferentiation. Am. J. Physiol. Endocrinol. Metab. 298, E1244–E1253. doi:
10.1152/ajpendo.00600.2009
Bostrom, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., et al. (2012).
A PGC1-alpha-dependent myokine that drives brown-fat-like development of
white fat and thermogenesis. Nature 481, 463–468. doi: 10.1038/nature10777
Choi, C. S., Savage, D. B., Abu-Elheiga, L., Liu, Z. X., Kim, S., Kulkarni,
A., et al. (2007). Continuous fat oxidation in acetyl-CoA carboxylase 2
knockout mice increases total energy expenditure, reduces fat mass, and
improves insulin sensitivity. Proc. Natl. Acad. Sci. U.S.A. 104, 16480–16485. doi:
10.1073/pnas.0706794104
Collins, S., Daniel, K. W., Petro, A. E., and Surwit, R. S. (1997). Strain-specific
response to beta 3-adrenergic receptor agonist treatment of diet-induced
obesity in mice. Endocrinology 138, 405–413.
Foster, M. T., Softic, S., Caldwell, J., Kohli, R., De Kloet, A. D., and Seeley, R. J.
(2013). Subcutaneous adipose tissue transplantation in diet-induced obesemice
attenuates metabolic dysregulation while removal exacerbates it. Physiol Rep.
1:e00015. doi: 10.1002/phy2.15
Galgani, J. E., Kelley, D. E., Albu, J. B., Krakoff, J., Smith, S. R., Bray, G. A., et al.
(2013). Adipose tissue expression of adipose (WDTC1) gene is associated with
lower fat mass and enhanced insulin sensitivity in humans. Obesity (Silver.
Spring). 21, 2244–2248. doi: 10.1002/oby.20371
Ghorbani, M., Claus, T. H., and Himms-Hagen, J. (1997). Hypertrophy of brown
adipocytes in brown and white adipose tissues and reversal of diet-induced
obesity in rats treated with a beta3-adrenoceptor agonist. Biochem. Pharmacol.
54, 121–131. doi: 10.1016/S0006-2952(97)00162-7
Ghorbani, M., and Himms-Hagen, J. (1997). Appearance of brown adipocytes
in white adipose tissue during CL 316,243-induced reversal of obesity and
diabetes in Zucker fa/fa rats. Int. J. Obes. Relat. Metab. Disord. 21, 465–475.
doi: 10.1038/sj.ijo.0800432
Giordano, A., Morroni, M., Carle, F., Gesuita, R., Marchesi, G. F., and Cinti,
S. (1998). Sensory nerves affect the recruitment and differentiation of rat
periovarian brown adipocytes during cold acclimation. J. Cell Sci. 111(Pt 17),
2587–2594.
Gong, F. Y., Deng, J. Y., Zhu, H. J., Pan, H., Wang, L. J., and Yang, H. B.
(2010). Fatty acid synthase and hormone-sensitive lipase expression in liver are
involved in zinc-alpha2-glycoprotein-induced body fat loss in obesemice.Chin.
Med. Sci. J. 25, 169–175. doi: 10.1016/S1001-9294(10)60043-0
Gong, F. Y., Zhang, S. J., Deng, J. Y., Zhu, H. J., Pan, H., Li, N. S., et al. (2009). Zinc-
alpha2-glycoprotein is involved in regulation of body weight through inhibition
of lipogenic enzymes in adipose tissue. Int. J. Obes. (Lond.) 33, 1023–1030. doi:
10.1038/ijo.2009.141
Gonzalez, E., and Mcgraw, T. E. (2009). Insulin-modulated Akt subcellular
localization determines Akt isoform-specific signaling. Proc. Natl. Acad. Sci.
U.S.A. 106, 7004–7009. doi: 10.1073/pnas.0901933106
Granneman, J. G., Li, P., Zhu, Z., and Lu, Y. (2005). Metabolic and
cellular plasticity in white adipose tissue I: effects of beta3-adrenergic
receptor activation. Am. J. Physiol. Endocrinol. Metab. 289, E608–E616. doi:
10.1152/ajpendo.00009.2005
Homma, H., Kurachi, H., Nishio, Y., Takeda, T., Yamamoto, T., Adachi, K., et al.
(2000). Estrogen suppresses transcription of lipoprotein lipase gene. Existence
of a unique estrogen response element on the lipoprotein lipase promoter. J.
Biol. Chem. 275, 11404–11411. doi: 10.1074/jbc.275.15.11404
Ioannides-Demos, L. L., Piccenna, L., and Mcneil, J. J. (2011). Pharmacotherapies
for obesity: past, current, and future therapies. J. Obes. 2011:179674. doi:
10.1155/2011/179674
Lampidonis, A. D., Rogdakis, E., Voutsinas, G. E., and Stravopodis, D. J. (2011).
The resurgence of Hormone-Sensitive Lipase (HSL) in mammalian lipolysis.
Gene 477, 1–11. doi: 10.1016/j.gene.2011.01.007
Li, W., Liu, J., He, P., Ni, Z., Hu, Y., Xu, H., et al. (2013). Hydroxysaﬄor
yellow A protects methylglyoxal-induced injury in the cultured human
brain microvascular endothelial cells. Neurosci. Lett. 549, 146–150. doi:
10.1016/j.neulet.2013.06.007
Li, Y., Wang, J., Gu, T., Yamahara, J., and Li, Y. (2014). Oleanolic acid
supplement attenuates liquid fructose-induced adipose tissue insulin resistance
through the insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt
signaling pathway in rats. Toxicol. Appl. Pharmacol. 277, 155–163. doi:
10.1016/j.taap.2014.03.016
Liu, L., Duan, J. A., Tang, Y., Guo, J., Yang, N., Ma, H., et al. (2012). Taoren-
Honghua herb pair and its main components promoting blood circulation
through influencing on hemorheology, plasma coagulation and platelet
aggregation. J. Ethnopharmacol. 139, 381–387. doi: 10.1016/j.jep.2011.11.016
Liu, S. X., Zhang, Y., Wang, Y. F., Li, X. C., Xiang, M. X., Bian, C., et al. (2012).
Upregulation of heme oxygenase-1 expression by hydroxysaﬄor yellow A
conferring protection from anoxia/reoxygenation-induced apoptosis in H9c2
cardiomyocytes. Int. J. Cardiol. 160, 95–101. doi: 10.1016/j.ijcard.2011.03.033
Frontiers in Pharmacology | www.frontiersin.org 8 May 2016 | Volume 7 | Article 127
Zhu et al. Safflower Yellow Improved Insulin Sensitivity
Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods 25, 402–408. doi: 10.1006/meth.2001.1262
Lucas, S., Taront, S., Magnan, C., Fauconnier, L., Delacre, M., Macia, L., et al.
(2012). Interleukin-7 regulates adipose tissue mass and insulin sensitivity
in high-fat diet-fed mice through lymphocyte-dependent and independent
mechanisms. PLoS ONE 7:e40351. doi: 10.1371/journal.pone.0040351
Mora, A., Komander, D., Van Aalten, D. M., and Alessi, D. R. (2004). PDK1, the
master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 15,
161–170. doi: 10.1016/j.semcdb.2003.12.022
Neeland, I. J., Ayers, C. R., Rohatgi, A. K., Turer, A. T., Berry, J. D., Das, S. R., et al.
(2013). Associations of visceral and abdominal subcutaneous adipose tissue
with markers of cardiac and metabolic risk in obese adults. Obesity (Silver.
Spring). 21, E439–E447. doi: 10.1002/oby.20135
Ohno, H., Shinoda, K., Spiegelman, B. M., and Kajimura, S. (2012). PPARgamma
agonists induce a white-to-brown fat conversion through stabilization of
PRDM16 protein. Cell Metab. 15, 395–404. doi: 10.1016/j.cmet.2012.01.019
Padwal, R., Li, S. K., and Lau, D. C. (2003). Long-term pharmacotherapy
for obesity and overweight. Cochrane Database Syst. Rev. Cd004094. doi:
10.1002/14651858.CD004094.pub2
Pickar, J. H., Thorneycroft, I., and Whitehead, M. (1998). Effects of hormone
replacement therapy on the endometrium and lipid parameters: a review of
randomized clinical trials, 1985 to 1995.Am. J. Obstet. Gynecol. 178, 1087–1099.
doi: 10.1016/S0002-9378(98)70553-8
Riant, E., Waget, A., Cogo, H., Arnal, J. F., Burcelin, R., and Gourdy, P. (2009).
Estrogens protect against high-fat diet-induced insulin resistance and glucose
intolerance in mice. Endocrinology 150, 2109–2117. doi: 10.1210/en.2008-0971
Seale, P., Conroe, H. M., Estall, J., Kajimura, S., Frontini, A., Ishibashi, J., et al.
(2011). Prdm16 determines the thermogenic program of subcutaneous white
adipose tissue in mice. J. Clin. Invest. 121, 96–105. doi: 10.1172/JCI44271
Song, L., Zhu, Y., Jin, M., and Zang, B. (2013). Hydroxysaﬄor yellow
a inhibits lipopolysaccharide-induced inflammatory signal transduction
in human alveolar epithelial A549 cells. Fitoterapia 84, 107–114. doi:
10.1016/j.fitote.2012.11.004
Steinberg, G. R., and Kemp, B. E. (2009). AMPK in Health and Disease. Physiol.
Rev. 89, 1025–1078. doi: 10.1152/physrev.00011.2008
Virtanen, K. A., Iozzo, P., Hallsten, K., Huupponen, R., Parkkola, R., Janatuinen, T.,
et al. (2005). Increased fat mass compensates for insulin resistance in abdominal
obesity and type 2 diabetes: a positron-emitting tomography study.Diabetes 54,
2720–2726. doi: 10.2337/diabetes.54.9.2720
Vitali, A., Murano, I., Zingaretti, M. C., Frontini, A., Ricquier, D., and Cinti,
S. (2012). The adipose organ of obesity-prone C57BL/6J mice is composed
of mixed white and brown adipocytes. J. Lipid Res. 53, 619–629. doi:
10.1194/jlr.M018846
Wang, C., Wang, C., Ma, C., Huang, Q., Sun, H., Zhang, X., et al. (2014).
Hydroxysaﬄor yellow A of Carthamus tinctorius attenuates lung injury of aged
rats exposed to gasoline engine exhaust by down-regulating platelet activation.
Phytomedicine 21, 199–206. doi: 10.1016/j.phymed.2013.09.018
Wang, F. Q. (2008). Effects of saﬄower yellow on the hemodynamics and
the protein expression of Akt, eNOS and PKC in the myocardium of
ischemia reperfusion. Chin. J. Misdiagn. 8, 7391–7392. doi: 10.3969/j.issn.1009-
6647.2008.30.074
Wu, J., Bostrom, P., Sparks, L. M., Ye, L., Choi, J. H., Giang, A. H., et al. (2012).
Beige adipocytes are a distinct type of thermogenic fat cell inmouse and human.
Cell 150, 366–376. doi: 10.1016/j.cell.2012.05.016
Yanovski, S. Z., and Yanovski, J. A. (2014). Long-term drug treatment
for obesity: a systematic and clinical review. JAMA 311, 74–86. doi:
10.1001/jama.2013.281361
Yu, T., Qi, Z. X., Yu, H., Zhang, Z. Y., and Zhong,W. H. (2011). Influence of HYSA
on steroid-induced BMSCs adipogenic differentiation. J. Fujian. Univ. TCM 21,
24–27 [34]. doi: 10.3969/j.issn.1004-5627.2011.06.008
Zang, B. X., Jin, M., and Li, J. R. (2008). Large scale preparation of pure
Hydroxysaﬄor Yellow A by macroporus resin-gel column chromatography. J.
Cardiovasc. Pulm. Dis. 27, 363–365. doi: 10.3969/j.issn.1007-5062.2008.06.015
Zhang, H. Y., Chen, M., and Xiong, W. S. (2010). Experimental study on
the antihtrombotic activity and regulating effect in blood lipids of saﬄor
yellow (SY). Chin. J. Lab. Diagn. 14, 1028–1031. doi: 10.3969/j.issn.1007-
4287.2010.07.019
Zhu, H. J., Wang, L. J., Wang, X. Q., Pan, H., Li, N. S., Yang, H. B., et al. (2014).
Hormone-sensitive lipase is involved in the action of hydroxysaﬄor yellow A
(HYSA) inhibiting adipogenesis of 3T3-L1cells. Fitoterapia 93, 182–188. doi:
10.1016/j.fitote.2014.01.001
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Zhu, Wang, Pan, Dai, Li, Wang, Yang and Gong. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 9 May 2016 | Volume 7 | Article 127
